Dr. Racke: Two things come to mind.
First, continued progress depends on sustained investment in research. Neurological diseases require long-term studies, and interruptions in funding can delay discoveries and slow the development of new therapies.
Second, despite remarkable advances, we still don't fully understand many of the mechanisms driving neurological disease. Multiple sclerosis is a good example. We can now control inflammation remarkably well, preventing relapses and new lesions in many patients. Yet some continue to experience neurodegeneration and disability progression despite effective treatment. That tells us there are important disease processes we have yet to understand.